EMA Authorised: Amversio (betaine) — SERB SA

View source ↗

Summary

The European Medicines Agency has authorized Amversio as a betaine product for homocystinuria, with SERB SA as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homocystinuria

Drugs mentioned

• Amversio (betaine)

Snippet

Status: Authorised. Therapeutic area: Homocystinuria. MAH: SERB SA. Decision date: 10/03/2026